HealthEquity (NASDAQ:HQY – Free Report) had its target price increased by BTIG Research from $110.00 to $115.00 in a report published on Friday morning, Marketbeat Ratings reports. BTIG Research currently has a buy rating on the stock.
Other equities research analysts have also recently issued research reports about the stock. Citigroup reiterated a “market outperform” rating on shares of HealthEquity in a research report on Monday, June 1st. BMO Capital Markets raised shares of HealthEquity from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $85.00 to $105.00 in a research note on Thursday, April 9th. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a research note on Tuesday, May 26th. Wells Fargo & Company set a $111.00 price objective on shares of HealthEquity in a report on Monday, June 1st. Finally, Royal Bank Of Canada boosted their target price on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $110.93.
View Our Latest Research Report on HealthEquity
HealthEquity Stock Performance
HealthEquity (NASDAQ:HQY – Get Free Report) last released its quarterly earnings data on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.13. The firm had revenue of $354.64 million during the quarter, compared to analyst estimates of $352.02 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.HealthEquity’s quarterly revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. On average, sell-side analysts predict that HealthEquity will post 3.92 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, EVP Michael Henry Fiore sold 3,142 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $95.00, for a total value of $298,490.00. Following the completion of the sale, the executive vice president owned 59,113 shares of the company’s stock, valued at $5,615,735. This trade represents a 5.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Delano Ladd sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $90.00, for a total transaction of $675,000.00. Following the completion of the sale, the executive vice president directly owned 91,141 shares of the company’s stock, valued at approximately $8,202,690. This represents a 7.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 17,905 shares of company stock valued at $1,651,280. Insiders own 1.60% of the company’s stock.
Institutional Investors Weigh In On HealthEquity
Institutional investors and hedge funds have recently made changes to their positions in the company. Acumen Wealth Advisors LLC acquired a new position in shares of HealthEquity during the fourth quarter valued at $27,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of HealthEquity by 1,723.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $28,000 after purchasing an additional 293 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of HealthEquity during the 4th quarter worth approximately $28,000. Leonteq Securities AG grew its position in shares of HealthEquity by 159.9% during the 1st quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after buying an additional 235 shares during the period. Finally, Axiom Investment Management LLC bought a new stake in shares of HealthEquity during the first quarter worth approximately $33,000. Institutional investors own 99.55% of the company’s stock.
About HealthEquity
HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Read More
- Five stocks we like better than HealthEquity
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.
